Pleiotropic effects of statins in atrial fibrillation patients: The evidence

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 533-551

  Hadi, Hadi A R ^a   Mahmeed, Wael Al ^a   Suwaidi, Jassim Al ^a   Ellahham, Samer ^a  

^a SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

Author keywords

Atrial fibrillation; Pleiotropic effects; Statins

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PLACEBO; PRAVASTATIN; SIMVASTATIN; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT;

ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEFIBRILLATOR; DISEASE ASSOCIATION; DRUG EFFECT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; PAROXYSMAL HEART ATRIUM FIBRILLATION; PERICARDITIS; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; ANIMAL; ANIMAL MODEL; CATHETER ABLATION; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; HEART PACING; META ANALYSIS; RISK FACTOR;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; CORONARY ARTERY DISEASE; ELECTRIC COUNTERSHOCK; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS AS TOPIC; MODELS, ANIMAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70349252195     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s4841     Document Type: Review

References (115)

1. Mihm MJ Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104:174-180.
2. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing - induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 2001;89:e32-e38.
3. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006-3010.
4. Gaudino M, Andreotti F, Zamparelli R, et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation. 2003;108(Suppl 1):II195-199.
5. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26:2083-2092.
6. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136-149.
7. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512-518.
8. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750-1756.
9. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation. 2003;107:258-263.
10. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426-431.
11. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92:1379-1983.
12. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92:1343-1345.
13. Marín F, Pascual DA, Roldán V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol. 2006;97(1):55-60.
14. Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle: evidence for electrical uncoupling of side-to-side fiber connections with increasing age. Cardiovasc Res. 1986;58: 356-371.
15. Schotten U, Ausma J, Stellbrink C, Hanrath P, Allessie MA. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation. 2001;103:691-698.
16. Kucera JP, Rudy Y. Mechanistic insights into very slow conduction in branching cardiac tissue: a model study. Circ Res. 2001;89:799-806.
17. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002;54:361-379.
18. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90:400-405.
19. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.
20. Tsai CT, Lai LP, Kuo KT, et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation. 2008b;117(3):344-355.
21. Chello M, Spadaccio C, Patti G, et al. Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation. Atherosclerosis. 2008;197(2):588-595.
22. Neuman RB, Bloom HL, Shukrullah I, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem. 2007;53(9):1652-1657.
23. Spodick DH. Arrhythmias during acute pericarditis: a prospective study of 100 consecutive cases. JAMA. 1976;235:39-41.
24. Morgera T, Di Lenarda A, Dreas L, et al. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electro-cardiographic changes. Am Heart J. 1992;124:455-467.
25. Bruins P, Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: post surgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542-3548.
26. Maixent JM, Paganelli F, Scaglione J, et al. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:612-617.
27. Chung MK, Martin DO, Sprecher D, et al. C-Reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891.
28. Shiroshita-Takeshita A, Schram G, Lavoie J, et al. Effect of Simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110:2313-2319.
29. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol. 2005a;102:321-326.
30. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation: Is there an association with early recurrence rates? Int J Clin Pract. 2005b;59:881-885.
31. Dudley SC Jr, Hoch NE, McCann LA, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation. 2005;112:1266-1273.
32. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol. 1974;112:2135-2147.
33. Volanakis JE, Wirtz KW. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature. 1979;281:155-157.
34. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol. 2001;56:375-380.
35. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(Suppl 4):37S-42S.
36. Conway DS, Buggins P, Hughes E, et al. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol. 2004a;4:508-510.
37. Conway DS, Buggins P, Hughes E, et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004b;43:2075-2082.
38. Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J. 2004;45:441-445.
39. Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005;95:764-767.
40. Asselbergs FW, van den Berg MP, Diercks GF, et al. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol. 2005;98:73-77.
41. Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels. 2005;20:45-49.
42. Anderson JL, Allen Maycock CA, Lappe DL, et al. Intermountain Heart Collaborative Study Group. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol. 2004;94:1255-1259.
43. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004;25:1100-1107.
44. Oral H, Knight BP, Ozaydin M, et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002;40:100-104.
45. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J. 2005;50:1064.
46. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 2002;4(Suppl 3):S233-S242.
47. Marcus GM, Whooley MA, Glidden DV, et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J. 2008;155(2):303-309.
48. Abdelhadi RH, Gurm HS, Van Wagoner DR, et al. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol. 2004;93:1176-1178.
49. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102:3104-3110.
50. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286: 64-70.
51. Amar D, Zhang H, Heerdt PM, et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest. 2005;128:3421-3427.
52. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardio-vascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183-198.
53. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of cholesterol reduction. Circulation. 2002;106:1447-1452.
54. Blanco-Colio LM, Tunon J, Martin-Ventura JL, et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12-23.
55. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation. 1996;94:2968-2974.
56. Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997;95:1945-1953.
57. Lee SH, Yu WC, Cheng JJ, et al. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation. 2000;101: 200-206.
58. Van Noord T, Van Gelder IC, Tieleman RG, et al. VERDICT: the Verapamil versus Digoxin Cardioversion Trial: a randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2001;12: 766-769.
59. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res. 2004;62:105-111.
60. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5:30-41.
61. Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation. 2003;107:2493-2498.
62. Gao L, Wang W, Li YL, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD (P) H oxidase. Circulation. 2005;112:1763-1770.
63. Tziakas DN, Chalikias GK, Stakos DA, et al. Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation. Am J Cardiol. 2008;101(2):199-202.
64. Jacobson J. Statins in endothelial signaling and activation. Antioxid Redox Signal. 2008;Sep 22. [Epub ahead of print]
65. Okazaki H, Minamino T,Wakeno M, et al. Statin prevents structural and electrical atrial remodeling in rat hypertensive heart failure induced by chronic inhibition of NO synthesis. Circulation. 2007; 116(Suppl II):140.
66. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007;74(1):75-84.
67. Liu T, Li L, Korantzopoulos P, et al. Statin use and development of atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126(2):160-170.
68. Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51(8):828-835.
69. Patel AA, White CM, Shah SA, et al. The relationship between statin use and atrial fibrillation. Curr Med Res Opin. 2007;23:1177-1185.
70. McLean DS, Ravid S, Blazing M, et al. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J. 2008;155(2):298-302.
71. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J. 2007;154:1140-1145.
72. Hanna IR, Dudley SC Jr, King-Hageman D, et al. Lipid-lowering therapy reduces the prevalence of atrial fibrillation (Abstract). New Orleans, LA: 2005 Heart Rhythm Society Scientific Sessions, May 4-7; 2005. p. 1-34.
73. Ramani G, Zahid M, Good CB, et al. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol. 2007;100(3):404-405.
74. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2004;93(6):780-782.
75. Watanabe E, Arakawa T, Uchiyama T, et al. High sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol. 2006;108(3):346-353.
76. Humphries KH, Lee M, Sheldon R, et al. CARAF Investigators. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J. 2007;154(5):908-913.
77. Loricchio ML, Cianfrocca C, Pasceri V, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2007;99(10):1421-1424.
78. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2006;97:1490-1493.
79. Al Chekakie MO, Akar JG, Wang F, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol. 2007;18(9):942-946.
80. Richter B, Derntl M, Marx M, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J. 2007;153(1):113-119.
81. Gillis AM, Morck M, Exner DV, et al. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation. Eur Heart J. 2008;29:1873-1880.
82. Tsai CT, Lai LP, Hwang JJ, et al. Atorvastatin prevents atrial fibrillation in patients with brady-arrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial. Am Heart J. 2008a;156(1):65-70.
83. Amit G, Katz A, Bar-On S, et al. Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker. Clin Cardiol. 2006;29(6):249-252.
84. Bhavnani SP, Coleman CI, White CM, et al. Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace. 2008;10(7):854-859.
85. Korantzopoulos P, Galaris D, Papaioannides D, et al. C-reactive protein and oxidative stress in atrial fibrillation. Int J Cardiol. 2003b;88:103-104.
86. Korantzopoulos P, Kolettis TM, Galaris D, et al. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol. 2007;115:135-143.
87. Korantzopoulos P, Galaris D, Papaioannides D, et al. The possible role of oxidative stress in heart failure and the potential of antioxidant intervention. Med Sci Monit. 2003a;9:RA120-125.
88. Liu T, Li G, Li L, et al. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol. 2007;49:1642-1648.
89. Musco S, Conway EL, Kowey PR. Drug therapy for atrial fibrillation. Med Clin North Am. 2008;92:121-141.
90. Shanes JG, Minadeo KN, Moret A, et al. Statin therapy in heart failure: prognostic effects and potential mechanisms. Am Heart J. 2007;154:617-623.
91. Tousoulis D, Charakida M, Stefanadi E, et al. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol. 2007;115:144-150.
92. Korantzopoulos P, Kokkoris S. The antioxidant effects of statins may extend beyond atherosclerosis: potential benefits for atrial fibrillation and heart failure. Atherosclerosis. 2004;175(1):187.
93. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3(6):853-876.
94. Kostapanos MS, Liberopoulos EN, Goudevenos JA, et al. Do statins have an antiarrhythmic activity? Cardiovasc Res. 2007;75:10-20.
95. Hanna IR, Heeke B, Bush H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006;3:881-886.
96. Dickinson MG, Hellkamp AS, Ip JH, et al. Statin therapy was associated with reduced atrial fibrillation and flutter in heart failure patients in SCD-HEFT. Heart Rhythm. 2006;3(Suppl):S49.
97. Coletta AP, Cullington D, Clark AL, et al. Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF. Eur J Heart Fail. 2008;10(12):1264-1267.
98. Spach MS, Dolber PC, Heidlage JF. Influence of the passive anisotropic properties on directional differences in propagation following modification of the sodium conductance in human atrial muscle. A model of reentry based on anisotropic discontinuous propagation. Circ Res. 1988;62:811-832.
99. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001;103:769-77.
100. Bruins P, Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: post surgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542-3548.
101. Amar D, Fleisher M, Zhang H. Elevated C-reactive protein but not troponin is associated with postoperative atrial fibrillation. Anesth Analg. 2002;94:S67.
102. Liu T, Li GP, Huang TG. Anti-inflammatory therapies in atrial fibrillation. Int J Cardiol. 2005;104:359-360.
103. Knayzer B, Abramov D, Natalia B, et al. Atrial fibrillation and plasma troponin I elevation after cardiac surgery: relation to inflammation-associated parameters. J Card Surg. 2007;22(2):117-123.
104. Kourliouros A, De Souza A, Roberts N, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg. 2008;85(5):1515-1520.
105. Subramaniam K, Koch CG, Bashour A, et al. Preoperative statin intake and morbid events after isolated coronary artery bypass grafting. J Clin Anesth. 2008;20(1):4-11.
106. Mariscalco G, Lorusso R, Klersy C, et al. Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery. Ann Thorac Surg. 2007;84(4):1158-1164.
107. Lertsburapa K, White CM, Kluger J, et al. Preoperative statins for the prevention of atrial fibrillation after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2008;135(2):405-411.
108. Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology. 2007;107(2):117-121.
109. Liakopoulos OJ, Choi YH, Haldenwang PL, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J. 2008;29(12):1548-1559.
110. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114:1455-1461.
111. Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J. 2008;156(2):373,e9-e16.
112. Ishii Y, Schuessler RB, Gaynor SL, et al. Inflammation of atrium after cardiac surgery is associated with in homogeneity of atrial conduction and atrial fibrillation. Circulation. 2005;111:2881-2888.
113. Tselentakis EV, Woodford E, Chandy J, et al. Inflammation effects on the electrical properties of atrial tissue and inducibility of post-operative atrial fibrillation. J Surg Res. 2006;135:68-75.
114. Lamm G, Auer J, Weber T, et al. Post-operative white blood cell count predicts atrial fibrillation after cardiac surgery. J Cardiothorac Vasc Anesth. 2006;20:51-56.
115. Virani SS, Nambi V, Razavi M, et al. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J. 2008;155(3):541-546.